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A B S T R A C T
Pituitary carcinomas (PCa) are extremely rare, indistinguishable from pituitary adenomas on histopathological
grounds and have a poor prognosis. Most PCa start as PRL or ACTH secreting tumors in males, with relapsing
invasive behaviour, refractoriness to medical and radiotherapy and increasing hormonal levels. The presence of
distant metastases is still required for the diagnosis of PCa. The association with genetic endocrine diseases must
be taken into account, since it adds further risk of evolution towards malignancy. Intradural spinal metastases
have also been reported, so a complete craniospinal MR evaluation is recommended, when clinically indicated.
We report a case of PCa, associated with MEN1 syndrome, with evidence of meningeal spread to the tentorium
cerebelli, clival dura and spinal drop metastases mimicking spinal nerves schwannomas.
1. Introduction
Pituitary carcinomas (PCa) are extremely rare (less than 0.5 % of all
pituitary tumours) [1], with a poor long-term prognosis [1–3]. The
aetiology is unknown but most of them develop from the malignant
transformation of a usually hormonally active invasive-aggressive
adenoma. There are no histological features to distinguish a PCa from
ordinary pituitary adenomas, therefore the diagnosis is very difficult
prior to metastatization [2]. We report a case of relapsing invasive pi-
tuitary adenoma with evidence of meningeal spread to the posterior
fossa and spine drop metastases. Moreover, we discuss the clinico-
neuroradiological signs suggestive of malignancy.
2. Clinical observation and imaging findings
The medical history of a 43-year-old man with relapsing pituitary
adenoma and multiple endocrine neoplasia type 1 (MEN1) syndrome is
reported. Patient gave written informed consent in accordance with the
Declaration of Helsinki for this case report.
In late 2004 at the age of 27, due to an erectile dysfunction, the
patient underwent laboratory investigations that revealed hyperpro-
lactinemia (serum prolactin: 4288 μU/mL). In August 2005 a pituitary
MRI showed the presence of a solid enhancing mass extending to the
suprasellar region (at that time a 0,5 T GE Vectra was used; see Fig. 1).
Dopamine agonist therapy was started and good control of serum pro-
lactin levels was obtained. In 2007 elevated levels of PRL were again
detected and a trans-nasal surgical excision (TNS) of the tumor was
performed. A questionable “Rathke cleft cyst” diagnosis resulted from
histological analysis.
In 2015 the patient underwent gonadotrophine stimulation to treat
azoospermia. In 2016, because of worsening prolactin hormone levels,
a pituitary MRI showed a recurrent invasive pituitary lesion, invading
the sphenoid sinus, extending beyond the suprasellar cistern and in-
vading the III ventricle, displacing the optic chiasm. A trans-nasal 3D
endoscopic extended approach was performed and histopathology was
consistent with atypical pituitary adenoma (WHO grade II: PRL+, GH-,
LH-, FSH-, TSH-, ACTH-; MIB1: 6–8 %). The post-operative course was
complicated by formation of an intraventricular hematoma, which was
removed, and by triventricular post haemorrhagic hydrocephalus
treated with ventriculo-peritoneal shunting. The patient experienced
bitemporal hemianopsia and complete hormonal substitution therapy
was necessary thereafter.
In the following two years after surgery, the neuroimaging findings
(thereafter a GE Signa HD 1.5 T was used) were stable with no signs of
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disease recurrence (Fig. 2). In February 2018 parasellar recurrence
occurred and fractionated radiotherapy (50 Gy x 25 fr) was delivered,
without complications. A control MRI showed partial regression of the
parasellar lesion, but revealed a focal thickening along the petroclival
profile and the tentorial surface, wrongly interpreted as radiation-in-
duced meningioma (Fig. 3). On subsequent follow-ups (January and
April 2019) a progressive growth of the petroclival tissue was reported,
with the onset of intralesional necrotic-cystic degeneration areas
(Fig. 4).
From August 2019 the patient started complaining of left sided
progressively increasing lombosciatalgia resistant to steroid treatment
and causing walking disturbances. A lumbar MRI showed three in-
traspecal rounded lesions consistent with drop metastases or multiple
schwannomas; the largest at the L3 level presented areas of necrotic-
cystic degeneration similar to those described in the petroclival region
(Fig. 5). An FDG-PET scan (GE PET-CT Discovery 690), detected hy-
percaptation of the radiotracer in the retroclival region and in the in-
traspecal space at the L3 level (Fig. 6). In January 2020 an L3 lami-
nectomy with complete microsurgical excision of the bigger lesion was
performed. At surgery the lesion appeared to originate from the filum
terminale. Histological diagnosis was of pituitary adenoma (PRL+,
synaptophysin+, chromogranin+, GATA3-, CKpool-, S100-, SOX10- ;
MIB1: 5%).
In February 2020 the patient presented with occipital headache not
responding to analgesics. A pituitary MRI revealed a huge increase in
volume of the heterogeneous petroclival and parasellar tissue, ex-
tending down to the atlanto-occipital joint, obliterating the foramen
magnum and the interpeduncular-prepontine cisterns, with
Fig. 1. Sagittal spin-echo (SE) T1-weighted (T1w) acquired after i.v. adminis-
tration of gadolinium (+Gd) demonstrating a solid enhancing mass (arrow)
that extends from the pituitary fossa to the chiasmatic cistern displacing the
optic chiasm.
Fig. 2. Sagittal fast-spin-echo (FSE) T1w + Gd acquired in 2017 after the
second surgical treatment. Findings are compatible with the result of the trans-
nasal surgical excision (dotted line) with no evidence of pathological tissue
outside the pituitary fossa.
Fig. 3. 3D Sagittal fast spoiled gradient-echo (FSPGR) T1w + Gd from 2018
showing a small token of pathological tissue along the petroclival profile
(arrow) misdiagnosed as radiation induced meningioma.
Fig. 4. Sagittal FSE T1w + Gd from 2019 showing increased volume of the
previously reported tissue along the petroclival profile (asterisk) which is now
characterized by an intralesional necrotic-cystic degeneration area (arrow).
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compressive effect on the brainstem and fourth ventricle (Fig.7). Mul-
tiple small solid lesions strictly connected with the tentorial cerebellar
surface (Fig. 8) were also demonstrated. New surgery, Gamma Knife
treatment or salvage radiotherapy have been ruled out and multi-
disciplinary evaluation is now pending to establish a possible man-
agement of this tumor. Temozolomide approach has been proposed
[4,5].
3. Discussion
Pituitary adenoma is one of the most common intracranial tumors,
representing 10%–15% of all intracranial neoplasms. About 5% of pi-
tuitary adenomas present as invasive lesions and in the most recent
WHO classification invasion is noted as an important feature to identify
clinically aggressive tumors [1,6–8]. Such adenomas, however, are not
histologically malignant; they are a subset of tumors prone to multiple
recurrences, resistant to any conventional treatment and radiotherapy
[9]. PCa is a very rare tumor, about 0,5% of all pituitary tumors, which
remains poorly understood. It is still not clear indeed if a PCa is a pi-
tuitary adenoma which undergoes malignant transformation or if a PCa
originates as an ex-novo malignancy [6], but usually it is the evolution
of an invasive aggressive hormonally active adenoma that recurs over
several years [10]. Both aggressive adenomas and carcinomas may
show the same features, as high p53 immunoreactivity, similar mitotic
activity and elevated Ki-67 labeling index. Pituitary carcinomas often
have a higher Ki-67 labeling index than atypical adenomas, but this
finding is seldom of diagnostic or prognostic value, even because no
criteria for Ki-67 cutoff values have been established. Conversely a Ki-
67 labeling index> 10 % in an aggressive adenoma is considered to
have high malignant potential [1,6,11]. Moreover, there are evidences
that not all the previously called atypical adenomas have a clinically
aggressive behaviour [9].
According to the 2017 WHO classification, the diagnosis of PCa
requires evidence of metastatic disease either as separate non-con-
tiguous foci within (craniospinal metastases) or outside (systemic me-
tastases) the central nervous system [5,8,12].
Fig. 5. Sagittal FSE T1w + Gd of the lumbar spine from September 2019
showing multiple intraspecal round dural solid lesions consistent with drop
metastasis (arrows). The largest is at the L3 level and also show areas of ne-
crotic-cystic degeneration as the tissue described along the petroclival profile
(see Fig. 4).
Fig. 6. FDG-PET examination (sagittal multiplanar reconstruction, MPR) from
October 2019 showing the radio tracer uptake only in the retroclival region and
in the intraspecal space at the L3 level.
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The clinical course of the case we described, is a typical example of
disease progression of a pituitary PRL secreting adenoma (once classi-
fied as atypical, WHO grade II), with a Ki-67 labeling index of 8%,
consistent with a greater risk of malignancy. The latency to metastatic
progression was 15 years but from the second TNS operation to meta-
static disease just two years have passed, and notwithstanding the
presence of a VP shunt, peritoneal seeding of the tumor did not occur.
In our patient, the spinal intradural lesions were surgically removed, a
diagnosis of pituitary PRL secreting adenoma metastasis was obtained,
consistent with the diagnosis of the sellar/suprasellar tumor.
Furthermore, considering the associated hereditary disorder (MEN1),
multiple spinal nerve schwannomas could be hypothesized. As a matter
of fact, it might have seemed that they originated from the spinal roots
rather than dural implants that are more frequently reported as dural
sac occupying masses [6,13–16].
On the other hand, metastatic lesions typically show neuror-
adiological characteristics similar to the initial lesion (round intradural
lesions with heterogeneous T2 hyperintensity with cystic components).
Therefore, in cases with pituitary lesions recurrences, to avoid mis-
diagnosis and detect drop metastasis whole spine MRI examination
should be considered in symptomatic patients.
Dural metastases are common, due to local invasion of the sub-
arachnoid space, with subsequent tumor seeding along the dura sur-
rounding the hemispheres, the cerebellum, and the cerebellopontine
angle [1,13,14]; moreover, distant spinal metastases, albeit very rare,
have also been reported as the result of dissemination of tumor cells in
the cerebrospinal fluid and seeding by gravity, or perilymphatic spread
along nerve roots. Intramedullary metastasis have been reported too,
even if these are exceptional [15]. Systemic localizations are also pos-
sible through lymphatic or hematogenous transport, probably via the
superior petrosal sinus drainage if the cavernous sinus is invaded by the
tumor; extracranial sites may include the liver, lymph nodes, bones, and
lungs [13,16,17]. MRI is the gold standard to detect pituitary pathology
and shows high efficacy in detecting metastatic lesions also [18], but to
perform a whole body scan a strong clinical suspicion of metastatic
disease should be present. Although invasiveness is not indicative of
malignancy, the evidence of invasion of sphenoid and cavernous sinus
on pituitary MRI, should be considered a “red flag” because of a higher
risk of developing a PCa [19], forcing strict, lifelong, follow ups.
Despite a radical surgical removal of the adenoma, persisting high
levels of hormones or progressive worsening of the secretory state
under adequate medical therapy, coupled with the results of the pa-
thological examination, may imply malignancy and might indicate the
presence of metastases. Moreover, the lack of efficacy of conventional
radiotherapy or Gamma Knife treatment in patients with invasive
hormonally active tumors, as shown by the clinical course of our case,
may also anticipate a more aggressive clinical course with a worse
prognosis [2,20].
In our case, a MEN1 syndrome was present. Only a few similar cases
of MEN1 syndrome associated with a pituitary carcinoma have been
described in the literature (including prolactin and plurihormonal se-
creting pituitary carcinomas) [21]. Thus, in patients with pituitary
adenomas with an aggressive behaviour, genetic endocrine disorders
must be evaluated, since MEN1 is usually associated with more ag-
gressive pituitary tumors and this may add further risk of possible
evolution towards malignancy. In particular, our patient showed a
specific mutation not previously described in the literature: exon 10,
1666 G>T (E556X).
In this case rapid enlargement of the tumor occurred after human
chorionic gonadotropin (hCG) hormone therapy for pituitary hypogo-
nadism-related infertility. Some studies reported evidences that exo-
genous hCG enhances the viability of cancer cells and promotes the
growth of tumors in mice [22]. Atypical pituitary adenomas might be at
risk of progression during hCG hormone therapy, but further studies are
needed to confirm this theory.
Finally, our case could suggest a possible inductive role of radio-
therapy for pituitary carcinoma development. Indeed, many studies
emphasize the risk of radiation induced tumors after fractionated
radiotherapy, that would seem to be linked to different factors such
individual genetic susceptibility [23,24].
As illustrated by our case, frequent endocrinological and neuroi-
maging surveillance is crucial for early detection of malignant trans-
formation with possible metastatic progression of aggressive pituitary
tumors.
Fig. 7. Sagittal Fluid Attenuated Inversion Recovery (FLAIR) T1w + Gd from
February 2020 that reveals a huge increase of the heterogeneous petroclival
tissue obliterating periaxial cisterns with mass effect on the brainstem. A dural
metastasis is also appreciable (arrow).
Fig. 8. Axial MPR from 3D Sagittal FSPGR T1w + Gd from February 2020
revealing multiple small solid enhancing lesions consistent with dural metas-
tasis strictly connected with tentorium cerebelli.
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4. Conclusion
Malignant transformation of a pituitary adenoma into a pituitary
carcinoma is very rare, but aggressive PRL or ACTH secreting ade-
nomas, especially in young male patients, should be submitted to strict
endocrinological and neuroradiological follow ups as they have a
higher potential of clinically malignant transformation. This case is an
excellent example of disease progression over sixteen years, with re-
lapsing pituitary adenoma, increasing level of prolactin not responding
to therapy, development of dural metastasis and intraspecal drop me-
tastasis as the results of a malignant progression. In these rare situa-
tions, investigation of the underlying genetics is suggested since some
endocrine syndromes, like MEN1, may add a further risk of malignant
transformation. Even the eventual role of HGC therapy on tumor evo-
lution should be more thoroughly investigated, particularly when
neuroendocrine tumors are involved. MRI shows high sensitivity in
assessing pituitary disease progression; a complete MRI craniospinal
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